Reproterol is a short-acting[1] β2 adrenoreceptor agonist used in the treatment of asthma.[2]
Clinical data | |
---|---|
AHFS/Drugs.com | International Drug Names |
Routes of administration | Inhalation (MDI), IV |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.053.579 |
Chemical and physical data | |
Formula | C18H23N5O5 |
Molar mass | 389.412 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
It was patented in 1965 and came into medical use in 1977.[3]
Stereochemistry
editReproterol contains a stereocenter and is chiral. There are thus two enantiomers, the (R)-form and the (S)-form. The commercial preparations contain the drug as a racemate, an equal mixture of the two enantiomers.[4]
Enantiomers of reproterol | |
---|---|
(R)-Reproterol CAS number: 210710-33-1 |
(S)-Reproterol CAS number: 210710-34-2 |
References
edit- ^ Küpper T, Goebbels K, Kennes LN, Netzer NC (December 2012). "Cromoglycate, reproterol, or both--what's best for exercise-induced asthma?". Sleep & Breathing = Schlaf & Atmung. 16 (4): 1229–35. doi:10.1007/s11325-011-0638-2. PMID 22198635. S2CID 10032756.
- ^ Virchow JC (1999). "Reproterol: beta-2-agonist, theophylline, or both?". Respiration; International Review of Thoracic Diseases. 66 (3): 210–1. doi:10.1159/000029379. PMID 10364735. S2CID 203732706.
- ^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 54X. ISBN 9783527607495.
- ^ Rote Liste 2017 – Arzneimittelverzeichnis für Deutschland (einschließlich EU-Zulassungen und bestimmter Medizinprodukte). Vol. 57. Frankfurt/Main: Rote Liste Service GmbH. 2017. p. 196. ISBN 978-3-946057-10-9.